TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells

Abstract Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient basis. Understanding cell and molecular mechanisms determining frac...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Selvakumar Anbalagan, Cecilia Ström, Jessica A. Downs, Penny A. Jeggo, David McBay, Anna Wilkins, Kai Rothkamm, Kevin J. Harrington, John R. Yarnold, Navita Somaiah
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/c9e7edacfb97484e949e3d81da55de3a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!